Metformin may lower colorectal cancer risk by stopping precancerous lesion formation
the ONA take:
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions, according to a study published online ahead of print in the journal Cancer Epidemiology, Biomarkers & Prevention.
Because previous research has suggested that metformin may lower colorectal cancer risk in patients with diabetes and most colorectal cancers originate in precancerous adenomas, researchers from Kaiser Permanente in California and the University of Pennsylvania Perelman School of Medicine sought to determine whether metformin use lowered colorectal adenoma risk following polypectomy in patients with type 2 diabetes.
Researchers retrospectively analyzed data from 2,142 patients age 40 to 89 years with type 2 diabetes, at least one adenoma at baseline colonoscopy, and at least one adenoma at repeat colonoscopy 1 to 10 years from baseline colonoscopy.
Results showed that metformin use was associated with lower adenoma recurrence risk. Researchers found that the association was stronger with increasing total metformin dose.
“Our study suggests a potential benefit of metformin use in lowering the risk of subsequent adenomas after polypectomy in patients with type 2 diabetes,” the authors conclude.
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|